The immunology drug Skyrizi (risankizumab) from AbbVie ranks first for the third consecutive year in the U.S. pharmaceutical TV ad spending ranking compiled by iSpot.TV.
Estimated national TV ad spending for Skyrizi in 2025 reached $439.6 million, compared to $377.3 million in 2024. Throughout the year, American television aired 13 Skyrizi promotional spots — eight about psoriasis treatment, four about ulcerative colitis/Crohn’s disease, and one about psoriatic arthritis, notes Fierce Pharma.
In second place is another immunology drug — Tremfya (guselkumab) from Johnson & Johnson, which jumped four positions in a year thanks to a 2.7-fold increase in ad spending to $431 million. Last year, 15 Tremfya commercials aired — seven about psoriasis, four about ulcerative colitis/Crohn’s disease, and four about psoriatic arthritis.
Rounding out the top three is Skyrizi’s counterpart from the same manufacturer — AbbVie’s Rinvoq (upadacitinib), which held second place in the previous ranking. The company spent $376.4 million on TV advertising for the drug last year (compared to $338.1 million in 2024). Rinvoq was promoted by 11 commercials — five about eczema treatment, three about ulcerative colitis/Crohn’s disease, and three about arthritis.
The GLP-1 agonist for obesity treatment, Wegovy (semaglutide) from Novo Nordisk, retained fourth place: spending on airing just three of its commercials in 2025 totaled $298.1 million ($263.2 million the year before). Closing the top five is the immunology drug Dupixent (dupilumab), a joint development by Sanofi and Regeneron: it fell two positions due to a reduction in its ad budget to $241.3 million from $279.2 million in 2024. Last year, TV broadcasts aired 19 Dupixent commercials: 10 focused on eczema therapy, seven on asthma, and two on gastrointestinal diseases.
Pharmaceutical companies most frequently chose broadcasts of National Football League (NFL) games to air their commercials, culminating in the final — the Super Bowl. It is the largest television and cultural event of the year in the United States, famous for its expensive commercials and grand superstar show.